For early nanobody discovery, an immune library is usually the stronger starting point when you can immunize an appropriate camelid and your target is available in a biologically relevant form. A premade library is often the more practical choice when you need to begin screening quickly, cannot immunize, or want to explore targets that are difficult to use in an immunization program. Neither approach guarantees a functional veterinary nanobody: target format, screening design, and validation against the intended species and application remain decisive. At NBbiolab, we help veterinary research teams compare these routes against their target, timeline, and evidence requirements before selecting a discovery plan.
You can find more information on our web, so please take a look.
An immune library is made from antibody-producing cells collected after an animal has been exposed to a target antigen, commonly through a planned immunization program. The resulting repertoire can be enriched for target-reactive sequences, although enrichment depends on the antigen, immune response, and subsequent screening. A premade library is assembled before a specific customer project and can be screened against a new target without first running a project-specific immunization campaign. Its sequences may come from naïve, synthetic, or other documented sources, depending on the provider.
Both routes generally lead to selection of candidate nanobodies followed by sequence confirmation and experimental validation. The key difference is the starting repertoire: one is tailored through exposure to the target, while the other is already available for screening. In veterinary medicine, this choice should be connected to the intended application, such as research assays, pathogen recognition, diagnostics development, or exploratory therapeutic research. Each use calls for different validation and performance criteria.
| Decision factor | Immune library | Premade library |
|---|---|---|
| Starting point | Repertoire collected after target exposure | Existing repertoire screened against the project target |
| Target focus | Potentially enriched for the immunizing antigen | Not necessarily target-enriched before screening |
| Project start | Requires immunization and sample preparation before library screening | Can avoid a project-specific immunization stage |
| Best suited to | Projects where a tailored response and target-specific enrichment are priorities | Projects with access, timing, or immunization constraints |
| Important uncertainty | The animal may not develop a useful response to the chosen antigen | A suitable binder may not be present or recovered in the screening workflow |
An immune library is a strong option when your project has a well-characterized antigen and the goal is to prioritize binders that recognize it. This can be useful for veterinary pathogens, animal biomarkers, or species-specific proteins, provided the immunogen represents the relevant target form. For example, a recombinant protein may not display the same accessible regions as a native cell-surface protein or a protein in a complex biological sample. We recommend discussing antigen design and screening format together, rather than treating immunization as a standalone step.
The approach is less predictable when the target is poorly characterized, difficult to produce, or potentially harmful to the immunization host. It also adds project stages before selection can begin. In planning discussions, immune discovery campaigns are often estimated in the range of 6–12 weeks for immunization-related work, but actual duration varies with the animal program, sampling schedule, antigen, and provider workflow. This is a planning range, not a guaranteed project timeline.
A premade library can be attractive when a project needs to start screening without a new immunization campaign. It can also provide a route for targets where immunization is impractical, subject to the provider’s library source, access terms, and screening capability. For an early veterinary feasibility study, this can help teams assess whether a target is tractable before investing in a more tailored discovery route.
The trade-off is that the repertoire may not have been enriched against your target. The project therefore depends on the quality and suitability of the library, the selection method, and the screening conditions. Published and commercial library descriptions may cite design diversities around 109–1010 variants, but that figure alone does not establish functional coverage, accessible diversity, or likelihood of obtaining a useful binder. Ask what the stated number means and how it is measured.
Premade-library projects may avoid the cost and lead time associated with project-specific immunization, but total cost still depends on screening scope, hit characterization, and downstream validation. Immune-library projects require additional planning for antigen preparation, animal work, sampling, and library construction. The lowest initial quote is not necessarily the lowest-cost route if it excludes sequence recovery, specificity testing, or application-relevant validation.
If you are looking for more details, kindly visit NBbiolab.
For a first screening milestone, ask whether the supplier can define a realistic schedule in writing. Some workflows may reach an initial screening readout within 1–3 weeks after screening begins, but this does not include all upstream preparation, repeat selections, or validation, and should not be treated as a universal standard. Confirm which stages the estimate covers, what deliverables you receive, and what happens if the first screen produces no acceptable candidates.
Document the target species, protein sequence or strain, target form, and application before choosing a library. A nanobody intended to detect a canine biomarker in serum may require different specificity and matrix testing from one intended to recognize a viral antigen in a laboratory assay. If cross-reactivity matters, identify the related species or proteins that must be included in counter-screening. These details help the supplier design selection conditions around the real use case.
For an immune library, ask which antigen was used, how it was presented, and whether the provider can share project-relevant evidence of immune response or enrichment. For a premade library, ask about its source, construction method, stated diversity, sequence availability, and any access or licensing restrictions. In either case, clarify how candidates will be assessed for binding, specificity, expression, and reproducibility. A library’s headline size is only one part of the decision.
Agree on what counts as a successful candidate before the campaign begins. This may include binding to the intended target, lack of binding to specified related proteins, recognition in the intended assay format, and acceptable expression or stability for the next research step. Early validation should match the proposed veterinary application as closely as practical. A positive result in one selection format does not by itself establish suitability for a diagnostic or therapeutic use.
At NBbiolab, we approach library selection as a project-design decision rather than a one-size-fits-all recommendation. We can discuss target format, veterinary species, screening objectives, and the evidence needed to move candidates into your next research stage. Where the project calls for a custom route, our nanobody discovery planning can be aligned with the agreed target and evaluation criteria; available scope and timelines should be confirmed for each project.
Before requesting a proposal, prepare the target information, intended application, preferred timeline, and any known cross-reactivity requirements. We can then compare an immune-library strategy with an available premade-library route and identify key assumptions, deliverables, and risks. This early discussion helps ensure that the discovery plan is designed around useful experimental outcomes rather than library type alone.
Choose an immune library when a suitable immunization program is feasible and target-focused enrichment is central to your discovery goals. Choose a premade library when you need to avoid project-specific immunization, want an earlier screening start, or are testing feasibility with the available library options. For veterinary nanobody discovery, neither option should be selected without considering target species, antigen presentation, cross-reactivity, and the validation environment.
Your next step is to define the intended use and target format, then request a side-by-side proposal that separates screening from validation costs and timelines. Ask suppliers to explain library provenance, selection strategy, candidate deliverables, and limitations in writing. NBbiolab can help you assess those factors and shape a discovery plan suited to your veterinary research objectives.
For more information, please visit Immune vs Premade Libraries for Early Nanobody Discovery.